JUN 22·SEC EDGARLow
Coastlands Capital LP purchased $53K of KTTA (indirect holdings)
Coastlands Capital LP purchased 100,000 indirectly-held shares of Pasithea Therapeutics Corp. (KTTA) at $0.53 on 2026-06-17.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$KTTAW
Pasithea Therapeutics Corp.
Price · $KTTAWvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $KTTAW in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $KTTAW in the last 30 days.
See all $KTTAW insider activity →Top stories · $KTTAWMore →
JUN 2·rttnews.com
Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis
Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.
APR 1·Stock Titan
KTTA SEC Filings - Pasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Pasithea Therapeutics (KTTA) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. Each filing is accompanied by an AI-generated summary, sentiment and impact scores, and end-of-day stock performance data. The platform aims to simplify access to critical regulatory disclosures with analytical insights and historical market reactions.
KTTAW sentiment & insider activity
Recent KTTAW coverage spans financial news, insider activity and regulation.
What's driving KTTAW
Coastlands Capital LP purchased 100,000 indirectly-held shares of Pasithea Therapeutics Corp. (KTTA) at $0.53 on 2026-06-17.
Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.
This page provides a comprehensive resource for investors and traders to access Pasithea Therapeutics (KTTA) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. Each filing is accompanied by an AI-generated summary, sentiment and impact scores, and end-of-day stock performance data. The platform aims to simplify access to critical regulatory disclosures with analytical insights and historical market reactions.
MIAMI, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. ( "Pasithea" or the "Company" ) ( Nasdaq: KTTA. KTTAW ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated ...
Pasithea Therapeutics Corp ( NASDAQ:KTTA ) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate, PAS-004, capped by a new $1 million grant from the ALS Association. Here's what investors need to know. KTTA is among today's top ...
alphai scores every news story that mentions KTTAW with an AI model for sentiment and relevance, and aggregates insider trades from Pasithea Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $KTTAW
Score
Coastlands Capital LP purchased $53K of KTTA (indirect holdings)
Coastlands Capital LP purchased 100,000 indirectly-held shares of Pasithea Therapeutics Corp. (KTTA) at $0.53 on 2026-06-17.
2 min read
Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis
Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.
3 min readKTTA SEC Filings - Pasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Pasithea Therapeutics (KTTA) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. Each filing is accompanied by an AI-generated summary, sentiment and impact scores, and end-of-day stock performance data. The platform aims to simplify access to critical regulatory disclosures with analytical insights and historical market reactions.
3 min readPasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
MIAMI, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. ( "Pasithea" or the "Company" ) ( Nasdaq: KTTA. KTTAW ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated ...
3 min read
Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today - Pasithea Therapeutics (NASDAQ:KTTA)
Pasithea Therapeutics Corp ( NASDAQ:KTTA ) shares are trading sharply higher Wednesday morning after a string of upbeat updates on its lead drug candidate, PAS-004, capped by a new $1 million grant from the ALS Association. Here's what investors need to know. KTTA is among today's top ...
2 min read
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)
-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and ...
3 min read
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)
-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.
3 min readPasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 8, 2025 in NYC.
3 min readPasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)
MIAMI, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. KTTA ( "Pasithea" or the "Company" ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management's live presentation at the ...
2 min readPasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 10, 2025 in NYC.
3 min read